Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system
- PMID: 15224658
- DOI: 10.1080/07853890410031948
Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system
Abstract
Many neurodegenerative disorders such as Alzheimer's disease (AD) Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) are characterized by neuronal damage that may be caused by toxic, abnormal, aggregation-prone proteins. The purpose of this review is threefold: 1) to provide the reader with an overview of the genes involved in the abnormal processing and accumulation of misfolded proteins in neurodegenerative diseases using PD as a model disease; 2) to understand the cellular mechanisms for disposal of abnormal proteins, and the effects of toxic protein accumulation on ubiquitin proteasome system (UPS) and neuronal survival and 3) to discuss the development and challenges of cell culture and animal models for a rational and effective treatment for these disorders.
Similar articles
-
Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses.Neuromolecular Med. 2003;4(1-2):95-108. doi: 10.1385/NMM:4:1-2:95. Neuromolecular Med. 2003. PMID: 14528055 Review.
-
The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.Neuron. 2003 Oct 9;40(2):427-46. doi: 10.1016/s0896-6273(03)00606-8. Neuron. 2003. PMID: 14556719 Review.
-
Monitoring the ubiquitin/proteasome system in conformational diseases.Ageing Res Rev. 2003 Oct;2(4):433-49. doi: 10.1016/s1568-1637(03)00031-x. Ageing Res Rev. 2003. PMID: 14522245 Review.
-
The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders.Trends Neurosci. 2001 Nov;24(11 Suppl):S7-14. doi: 10.1016/s0166-2236(00)01998-6. Trends Neurosci. 2001. PMID: 11881748 Review.
-
Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.Exp Mol Med. 2015 Mar 13;47(3):e147. doi: 10.1038/emm.2014.117. Exp Mol Med. 2015. PMID: 25766616 Free PMC article. Review.
Cited by
-
Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice.Neurochem Res. 2013 Jan;38(1):201-7. doi: 10.1007/s11064-012-0909-8. Epub 2012 Nov 2. Neurochem Res. 2013. PMID: 23117422
-
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.J Clin Invest. 2007 Mar;117(3):648-58. doi: 10.1172/JCI29715. Epub 2007 Feb 15. J Clin Invest. 2007. PMID: 17304350 Free PMC article.
-
Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.Expert Rev Neurother. 2010 Jun;10(6):925-42. doi: 10.1586/ern.10.54. Expert Rev Neurother. 2010. PMID: 20518609 Free PMC article. Review.
-
Ataxin-7 and Non-stop coordinate SCAR protein levels, subcellular localization, and actin cytoskeleton organization.Elife. 2019 Jul 26;8:e49677. doi: 10.7554/eLife.49677. Elife. 2019. PMID: 31348003 Free PMC article.
-
Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation.PLoS One. 2017 Jun 29;12(6):e0179893. doi: 10.1371/journal.pone.0179893. eCollection 2017. PLoS One. 2017. PMID: 28662109 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
